Jean-François Bruxelle

Dr. Jean-François Bruxelle

Simon Fraser University, Faculty of Health Sciences
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Anaerobe
Verified
Journal Article
Closed access
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
AMA. Mizrahi
A. Mizrahi
SHS. Hoys
S. Hoys
ACA. Collignon
A. Collignon
CJC. Janoir
C. Janoir
SPSéverine Péchiné
Séverine Péchiné

23 May 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
SPSéverine Péchiné
Séverine Péchiné
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
CJClaire Janoir
Claire Janoir
ACAnne Collignon
Anne Collignon
New therapies are needed to prevent and treat Clostridium difficile infection and to limit the rise in antibiotic resistance. Besides toxins, several surface components have been characterized as colonization factors and have been shown as immunogenic. This review will focus on passive and active immunization strategies targeting C. difficile surface components to combat C. difficile. Concerning passive immunization, the first strategies used antisera raised against the entire bacterium to prevent infection in the hamster model. Then, surface components such as the flagellin and the S-layer proteins were used for immunization and the passive transfer of antibodies was protective in animal models. Passive immunotherapy with polyvalent immunoglobulins was used in humans and bovine immunoglobulin concentrates were evaluated in clinical trials. Concerning active immunization, vaccine assays targeting surface components were tested mainly in animal models, mouse models of colonization and hamster models of infection. Bacterial extracts, spore proteins and surface components of vegetative cells such as cell wall proteins, flagellar proteins, and polysaccharides were used as vaccine targets. Vaccine assays were performed by parenteral and mucosal routes of immunization. Both gave promising results and pave the way to development of new vaccines.

27 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
AMAssaf Mizrahi
Assaf Mizrahi
SHSandra Hoÿs
Sandra Hoÿs
ACAnne Collignon
Anne Collignon
CJClaire Janoir
Claire Janoir
SPSéverine Péchiné
Séverine Péchiné
The immunogenicity of bacterial flagellin has been reported in different studies. By its close interaction with the immune system, the flagellin represents an interesting adjuvant and vaccine candidate. Salmonella Typhimurium flagellin has already been tested as adjuvant to stimulate mucosal immunity. Here, we assessed the ability of Clostridium difficile flagellin FliC to act as a mucosal adjuvant, first combined with ovalbumin as antigen and second with a C. difficile surface protein, the precursor of the S-layer proteins SlpA. Using ovalbumin as antigen, we compared the gut mucosal adjuvanticity of FliC to Salmonella Typhimurium flagellin and cholera toxin. Two routes of immunization were tested in a mouse model: intra-rectal and intra-peritoneal, following which, gut mucosal and systemic antibody responses against ovalbumin (Immunoglobulins G and Immunoglobulins A) were analyzed by Enzyme-Linked Immuno Assay in intestinal contents and in sera. In addition, ovalbumin-specific immunoglobulin producing cells were detected in the intestinal lamina propria by Enzyme-Linked Immunospot. Results showed that FliC as adjuvant for immunization targeting ovalbumin was able to stimulate a gut mucosal and systemic antibody response independently of the immunization route. In order to develop a mucosal vaccine to prevent C. difficile intestinal colonization, we assessed in a mouse model the efficacy of FliC as adjuvant compared with cholera toxin co-administrated with the C. difficile S-layer precursor SlpA as antigen. After challenge, a significant decrease of C. difficile intestinal colonization was observed in immunized groups compared to the control group. Our results showed that C. difficile FliC could be used as adjuvant in mucosal vaccination strategy against C. difficile infections.

1 October 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
WBWilliam J. Bradshaw
William J. Bradshaw
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
AKAndrea Kovacs-Simon
Andrea Kovacs-Simon
Nicholas HarmerNicholas Harmer
Nicholas Harmer
CJClaire Janoir
Claire Janoir
SMStephen L. Michell
Stephen L. Michell
Clostridioides difficile is the primary cause of antibiotic-associated diarrhea and colitis, a healthcare-associated intestinal disease resulting in a significant fatality rate. Colonization of the gut is critical for C. difficile pathogenesis. The bacterial molecules essential for efficient colonization therefore offer great potential as vaccine candidates. Here we present findings demonstrating that the C. difficile immunogenic lipoprotein CD0873 plays a critical role in pathogen success in vivo We found that in a dixenic colonization model, a CD0873-positive strain of C. difficile significantly outcompeted a CD0873-negative strain. Immunization of mice with recombinant CD0873 prevented long-term gut colonization and was correlated with a strong secretory IgA immune response. We further present high-resolution crystal structures of CD0873, at 1.35-2.50 Å resolutions, offering a first view of the ligand-binding pocket of CD0873 and provide evidence that this lipoprotein adhesin is part of a tyrosine import system, an amino acid key in C. difficile infection. These findings suggest that CD0873 could serve as an effective component in a vaccine against C. difficile.

22 April 2019 in Journal of the American Chemical Society
Verified
Journal Article
Open access
NTNino Trattnig
Nino Trattnig
MBMarkus Blaukopf
Markus Blaukopf
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
RPRalph Pantophlet
Ralph Pantophlet
PKPaul Kosma
Paul Kosma
Lipooligosaccharides (LOS) from the bacterium Rhizobium radiobacter Rv3 are structurally related to antigenic mammalian oligomannoses on the HIV-1 envelope glycoprotein spike that are targets for broadly neutralizing anti-bodies. Here, we prepared a hybrid structure of viral and bacterial epitopes as part of a vaccine design strategy to elicit oligomannose-specific HIV-neutralizing antibodies using glycoconjugates based on the Rv3 LOS structure. Starting from a Kdo2GlcNAc2 tetrasaccharide precursor, a central orthogonally protected mannose trichloroacetimidate donor was coupled to OH-5 of the innermost Kdo residue. To assemble larger glycans, the N-acetylamino groups of the glucosamine units were converted to imides to prevent formation of unwanted imidate byproducts. Blockwise coupling of the pentasaccharide acceptor with an α-(1→2)-linked mannotriosyl trichloroacetimidate donor introduced the D1-arm fragment. Glycosylation of O-6 of the central branching mannose with an α-(1→2)-α-(1→6)-linked mannotriosyl trichloroacetimidate donor unit then furnished the undecasaccharide harboring a D3-arm extension. Global deprotection yielded the 3-aminopropyl ligand, which was activated as an isothiocyanate or adipic acid succinimidoyl ester and conjugated to CRM197. However, representative oligomannose-specific HIV-neutralizing antibodies bound the undecasaccharide conjugates poorly. Possible reasons for this outcome are discussed herein along with paths for improvement.

31 January 2018
Verified
Book Chapter
Closed access
PDF file
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
SPSéverine Péchiné
Séverine Péchiné
ACAnne Collignon
Anne Collignon